Dog ejected from car during Sunday crash found on sheep farm, herding sheep

UPDATE: JUNE 8 AT 10:28 A.M.
Tilly, the 2-year-old Border Collie who was ejected from a car Sunday during a crash, has been found.
He was found on a sheep farm, where he had apparently taken up the role of sheep herder. 

According to Tilly's owner, he has lost some weight since Sunday's crash and is now drinking lots of water but is otherwise healthy. 
PREVIOUS COVERAGE:
RATHDRUM, Idaho - The Idaho State Police (ISP) is investigation after a crash blocked SH-41 and Hayden Avenue on Sunday afternoon. 

ISP said they are looking for people who witnessed the incident. 
The crash happened when a GMC Yukon towing a white horse trailer attempted to turn south onto SH-41 when a Buick struck the GMC. 
The driver of the Buick, a man from Spirit Lake, was transported to a nearby hospital and was treated and released. No one else was injured.
During the crash, a dog was ejected from the rear of the GMC and is still missing. 
ISP said the dog is a 2-year-old Border Collie Heeler mix that goes by the name "Tilly". Tilly has no tail, a dark-colored face, weighs approximately 70 pounds, and was wearing a multi-colored plaid and tan-colored collar with a name tag containing the owner's contact information.
Tilly was last seen running northwest from the crash scene through the field. 
If you have any information on Tilly's whereabouts, you are asked to call State Police at (208) 209-7830, or the Kootenai County Sheriff Office's Animal Control at (208) 446-1300.

Introducing Private Click Measurement, PCM

On By Default

東洋代理疫苗破局羅生門　林全還原真相 - 今周刊

面對多日來的流言蜚語，東洋終於打破沉默，由董事長林全親上火線，解釋授權書「雞生蛋、蛋生雞」難題，並澄清內線交易、炒股等疑慮。

擠滿了人與攝影器材的會議室中，是東洋臨時召開的記者會，地點相同，氣氛卻與一個月前的亢奮截然不同。

 

十月十二日，東洋召開記者會宣布取得BioNTech（簡稱BNT）新冠疫苗有條件授權書，半個月後的十一月三日，東洋宣布授權破局之外，更陷入炒股疑雲。流言滿天飛的情況下，東洋董事長林全終於親上火線解釋。隨著BNT釋出疫苗治癒率達九成的消息曝光，外界也隨之恍然大悟，這正是東洋當初取得代理的同一款疫苗。外界更好奇的是，這支疫苗為何與台灣失之交臂。

 

政府採購量不如預期  東洋居中牽線失敗
 

記者會上林全表示，被質疑炒股，是他最難以接受的事情，自認「深惡痛絕內線交易」，早已在公司落實相關教育及政策，大方表示「歡迎來查」，並趁機說明東洋與德國藥廠BNT新冠疫苗代理背後涉及的政治問題、授權的來龍去脈。

 

記者會開頭，東洋總經理施俊良開宗明義指出，在國際慣例上，疫苗大都是由政府出面採購，各國取得的授權，政府是唯一買家。

 

而這次由東洋出面與BNT接觸，是因為早在今年三月，中國上海復星醫藥已經取得中、港、澳、台的BNT疫苗銷售代理權，也就是說，台灣要取得BNT的這劑疫苗，在沒有取得BNT台灣代理權之前，勢必要向中國醫藥商進行採購。

 

在這層複雜關係之下，林全說，當東洋有機會向BNT拿到台灣市場的獨家授權，就只能跳下來做。

 

事實上，正如十月十二日記者會上東洋所說的，在沒有開放自費疫苗的情形之下，東洋幾乎沒有利潤空間，更不期待能在公費疫苗上有賺頭。

 

對於外界質疑東洋到底有沒有取得授權書，林全形容，就是「雞生蛋、蛋生雞」。施俊良解釋，授權書並不是免費，預付款項是取得授權的商業條件之一，因此東洋取得BNT授權前，須預付大筆授權金；若沒有取得授權書，並確定訂購數量、

 

價格，東洋難以先行支付費用。也因此，東洋只能拿十月取得BNT開立的「有條件授權書」，居中代表BNT對政府商談。